Clinical implication of 14-3-3 epsilon expression in gastric cancer

Table 1 Clinicopathological characteristics and 14-3-3ε expression in gastric cancer samples (mean ± SD)

Variable	14-3-3ε protein expression				14-3-3ε mRNA expression
	Total	Ratio T/N	Adjusted P-value	95% CI	Total	Relative quantification	Adjusted P-value	95% CI
Gender
Male	10	0.418 ± 0.41	0.210	-0.13 to 0.63	18	1.404 ± 1.43	0.279	-1.38 to 0.40
Female	10	0.667 ± 0.47			13	0.898 ± 1.09
Onset (yr)
< 45	6	0.303 ± 0.26	0.052	-0.68 to -0.05	8	0.583 ± 0.31	0.028a	-1.49 to -0.25
≥ 45	14	0.646 ± 0.48			23	1.403 ± 1.45
Tumor location
Cardia	3	0.293 ± 0.11	0.067	0.03 to 0.56	4	0.796 ± 0.35	0.177	-0.12 to 1.23
Non-cardia	17	0.587 ± 0.47			27	1.250 ± 1.39
Laurén classification
Diffuse-type	4	0.244 ± 0.14	0.024a	0.12 to 0.65	13	1.119 ± 1.04	0.785	-0.69 to 1.07
Intestinal-type	16	0.618 ± 0.46			18	1.245 ± 1.49
Stage
Early	4	0.517 ± 0.64	0.921	-0.55 to 0.81	4	0.549 ± 0.38	0.046a	-1.41 to -0.16
Advanced	16	0.549 ± 0.41			27	1.287 ± 1.37
Tumor invasion
T1/T2	8	0.491 ± 0.49	0.674	-0.48 to 0.34	9	0.642 ± 0.33	0.052	-1.40 to -0.13
T3/T4	12	0.578 ± 0.43			22	1.417 ± 1.49
Lymph node metastasis
Absent	6	0.672 ± 0.57	0.510	-0.29 to 0.72	8	0.687 ± 0.53	0.069	-1.31 to -0.01
Present	14	0.488 ± 0.39			23	1.367 ± 1.45
Distant metastasis
Unknown/absent	16	0.557 ± 0.47	0.754	-0.42 to 0.47	23	0.978 ± 0.99	0.242	-2.25 to 0.51
Present	4	0.486 ± 0.37			8	1.807 ± 1.89

Differentially expressed between groups,

^aP < 0.05. T: Tumor gastric samples; N: Non-neoplastic gastric samples.